Neuropeptide Y (NPY) Inhibitors

Neuropeptide Y (NPY) is one of the most abundant peptides in the mammalian central nervous system and has various physiological roles, including appetite regulation, energy balance, and cardiovascular control. The NPY family includes peptides like NPY, peptide YY (PYY), and pancreatic polypeptide (PP). The primary strategy for modulating NPY signaling has been the development of receptor antagonists, given that NPY exerts its effects through its receptors (Y1, Y2, Y4, Y5, and Y6). However, targeting NPY directly, such as with antisense or siRNA approaches, represents an indirect method to inhibit the peptide's function. NPY signals primarily through a family of G-protein coupled receptors, identified as Y1, Y2, Y4, Y5, and Y6. These receptors differ in their distribution, ligand affinity, and downstream signaling, leading to diverse physiological effects upon activation.

NPY inhibitors predominantly aim at antagonizing these Y receptors. Several synthetic molecules have been developed to selectively target specific Y receptors. For instance, compounds have been identified that selectively antagonize the Y1 or Y2 receptors, with each exhibiting different activity profiles based on their selectivity. The development of these inhibitors generally relies on high-throughput screening, structural modifications of natural ligands, or structure-based drug design. Other methods to inhibit NPY function include targeting NPY peptide directly, either by degrading it or its release. Molecular approaches, such as antisense oligonucleotides or small interfering RNAs (siRNAs), can be employed to downregulate NPY expression at the mRNA level.